Screening decreases prostate cancer mortality:: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

被引:144
作者
Labrie, F [1 ]
Candas, B
Cusan, L
Gomez, JL
Bélanger, A
Brousseau, G
Chevrette, E
Lévesque, J
机构
[1] Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Med Ctr, Dept Med, Quebec City, PQ, Canada
[3] Univ Laval, Med Ctr, Dept Radiol, Quebec City, PQ, Canada
关键词
prostate cancer; screening; PSA; hormonal therapy;
D O I
10.1002/pros.20017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE. This clinical trial is aimed at evaluating the impact of prostate cancer screening on cancer-specific mortality. SUBJECTS AND METHODS. Forty-six thousand four hundred and eighty-six (46,486) men aged 45-80 years registered in the electoral roll of the Quebec city area were randomized in 1988 between screening and no screening. Screening included measurement of serum prostatic specific antigen (PSA) using 3.0 ng/ml as upper limit of normal and digital rectal examination (DRY) at first visit. At follow-up visits, serum PSA only was used. RESULTS. Seventy-four (74) deaths from prostate cancer occurred in the 14,231 unscreened controls while 10 deaths were observed in the screened group of 7,348 men during the first 11 years following randomization. Median follow-up of screened men was 7.93 years. A Cox proportional hazards model of the age at death from prostate cancer shows a 62% reduction (P < 0.002, Fisher's exact test) of cause-specific mortality in the screened men (P = 0.005). These results are in agreement with the continuous decrease of prostate cancer mortality observed in North America. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 53 条
[21]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[22]  
Labrie F, 1999, MOL UROL, V3, P217
[23]  
LABRIE F, 1993, CLIN INVEST MED, V16, P425
[24]   Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [J].
Labrie, F ;
Candas, B ;
Cusan, L ;
Gomez, JL ;
Diamond, P ;
Suburu, R ;
Lemay, M .
UROLOGY, 1996, 47 (02) :212-217
[25]   COMBINATION OF SCREENING AND PREOPERATIVE ENDOCRINE THERAPY - THE POTENTIAL FOR AN IMPORTANT DECREASE IN PROSTATE-CANCER MORTALITY [J].
LABRIE, F ;
CUSAN, L ;
GOMEZ, JL ;
DIAMOND, P ;
CANDAS, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (07) :2002-2013
[26]  
Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO
[27]  
2-B
[28]   DOWN-STAGING OF EARLY-STAGE PROSTATE-CANCER BEFORE RADICAL PROSTATECTOMY - THE FIRST RANDOMIZED TRIAL OF NEOADJUVANT COMBINATION THERAPY WITH FLUTAMIDE AND A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST [J].
LABRIE, F ;
CUSAN, L ;
GOMEZ, JL ;
DIAMOND, P ;
SUBURU, R ;
LEMAY, M ;
TETU, B ;
FRADET, Y ;
CANDAS, B .
UROLOGY, 1994, 44 (6A) :29-37
[29]  
LABRIE F, 1993, CLIN INVEST MED, V16, P499
[30]   SERUM PROSTATE SPECIFIC ANTIGEN AS PRE-SCREENING TEST FOR PROSTATE-CANCER [J].
LABRIE, F ;
DUPONT, A ;
SUBURU, R ;
CUSAN, L ;
TREMBLAY, M ;
GOMEZ, JL ;
EMOND, J ;
STAMEY, TA ;
LANGE, PH .
JOURNAL OF UROLOGY, 1992, 147 (03) :846-852